Hikma Pharmaceuticals

What Hikma Pharmaceuticals does

Hikma Pharmaceuticals PLC is a multinational generic and specialty pharmaceutical company founded in 1978 and headquartered in London, with operations across North America, MENA, and Europe. The company operates through three segments: Injectables (generic and specialty sterile injectables to hospitals), Rx (oral, respiratory, and other generics to North American retail), and Branded (branded generics and in-licensed products to retail and hospital customers across MENA). Hikma is the largest pharmaceutical company in the MENA region by sales and generated $3.349 billion in FY2025 revenue, up 7% year-over-year, with a geographic split of North America 59%, MENA 32.5%, and Europe 8.5%.

Hikma's technology base centers on generic pharmaceutical manufacturing across 29 plants and 3 R&D hubs, producing 12+ billion finished doses annually. Core capabilities include advanced aseptic vial filling, lyophilization, nasal inhalation production (Columbus, Ohio), and oral solid dose manufacturing. The company has expanded into biosimilars via ENOBY and XTRENBO (denosumab, January 2026) manufactured by Gedeon Richter under license. In 2025, Hikma launched 84 new products, secured 99 regulatory approvals, and submitted 139 filings. The pipeline is supported by recent acquisitions including Custopharm ($375M, 2021) and Xellia's US finished dosage form business ($135M, 2024), plus a $267M Ohio manufacturing expansion announced in 2026 as part of a $1B US commitment.

Hikma's revenue model is product-driven across diversified segments and geographies, with direct sales to hospitals and retail pharmacies, authorized generic partnerships (Collegium for Nucynta), and exclusive in-licensing for MENA distribution (Celltrion, Junshi, Rakuten, Melinta, Guardant Health). The company serves over 222 million patients globally, generates a 22.1% core operating margin, and is publicly traded on the LSE (HIK), NASDAQ Dubai, and OTC markets with BBB/stable ratings from S&P and Fitch. Distribution is direct enterprise sales to hospital systems and pharmacy chains, augmented by regional licensing partnerships that monetize Hikma's MENA commercial infrastructure for third-party innovators.

Name

Hikma Pharmaceuticals

Legal name

Hikma Pharmaceuticals PLC

Website

https://hikma.com

Company type

Public

Founded year

1978

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Hikma Pharmaceuticals is a multinational generic and specialty pharmaceutical company operating through Injectables, Rx, and Branded segments across North America, MENA, and Europe, producing 12+ billion doses annually across 29 manufacturing plants and serving 222 million patients.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Generic pharmaceuticals
• Injectable medicines
• Branded generics
• Pharmaceutical manufacturing
• Drug development

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. North America Generics (Rx): Supply of oral, respiratory and other generic and specialty products to the North America retail market
2. Injectables: Supply of generic and specialty injectable products to hospitals across markets, supported by manufacturing facilities in the US, Europe and MENA
3. MENA Branded: Branded generic and in-licensed products from local manufacturing facilities to retail and hospital customers across MENA
4. Generic Nasal Sprays: Expansion of generic nasal spray portfolio in the U.S.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Hikma Pharmaceuticals develops, manufactures, and markets generic, branded generic, and in-licensed pharmaceutical products across three operating segments: Rx (oral generics), Injectables, and Branded (primarily MENA). With approximately 9,400 employees and 29 manufacturing facilities worldwide, it supplies medicines to wholesalers, hospitals, pharmacies, and government health agencies in around 50 markets.

Differentiator

Problem solved

Functional benefit

Brands

• ENOBY: Denosumab biosimilar referencing Amgen's Prolia for treating osteoporosis in postmenopausal women
• XTRENBO
• Generic Nasal Spray Portfolio
• RYALTRIS
• KLOXXADO
• Mitigare
• Hikma Ventures

Products and services

• ENOBY Pharmaceutical product marketed by Hikma as part of its Rx/generics portfolio.
• XTRENBO Pharmaceutical product marketed by Hikma as part of its Rx/generics portfolio.
• Tofacitinib oral solution Oral solution formulation of tofacitinib marketed by Hikma within its generic pharmaceutical portfolio.
• RYALTRIS Pharmaceutical product marketed by Hikma within its in-licensed / specialty portfolio.
• KLOXXADO Pharmaceutical product marketed by Hikma within its specialty / branded portfolio.
• Mitigare Pharmaceutical product marketed by Hikma within its specialty / branded portfolio.
• Icosapent ethyl capsules Capsule formulation of icosapent ethyl marketed by Hikma within its generic pharmaceutical portfolio.
• Generic SAXENDA Generic pharmaceutical product marketed by Hikma corresponding to the SAXENDA reference brand.
• VYNDAMAX generic Generic pharmaceutical product marketed by Hikma corresponding to the VYNDAMAX reference brand.

Quantifiable outcome

• 222 million patients treated globally in 2025
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered minor, core and strategic.

• PfizerminorOthers · 28 April 2026Settlement agreement resolving patent infringement lawsuits regarding VYNDAMAX (tafamidis) for cardiomyopathy transthyretin-mediated amyloidosis. Settlements extend effective US patent expiry to June 1, 2031.
• OneSource Specialty PharmacoreGTM or Marketing Partner · 11 February 2026Manufacturing and commercialization partnership for generic Ozempic (semaglutide) in Saudi Arabia. OneSource manufactures in Bengaluru, Hikma handles exclusive MENA commercialization.
• AFT PharmaceuticalscoreGTM or Marketing PartnerExpanded agreement for commercialization of Combogesic injectable non-opioid pain medication into Saudi, Jordanian and Iraqi markets. Hikma holds exclusive commercialization rights for the MENA region.
• Celltrion HealthcarecoreGTM or Marketing PartnerExclusive licensing agreements for Vegzelma (biosimilar bevacizumab) and Remsima subcutaneous formulation for MENA region. Also exclusive licensing for Yuflyma (biosimilar adalimumab) and ustekinumab for MENA.
• Rakuten MedicalstrategicGTM or Marketing PartnerExclusive licensing agreement for Alluminox platform cancer treatment for MENA region.
• Junshi BiosciencesstrategicGTM or Marketing PartnerExclusive licensing agreement for toripalimab cancer treatment drug for MENA region.
• Melinta TherapeuticsstrategicGTM or Marketing PartnerExclusive licensing agreement for two novel anti-infectives for MENA region.
• Collegium PharmaceuticalcoreGTM or Marketing PartnerAuthorized generic partnership for Nucynta and Nucynta ER in the United States. Hikma supplies authorized generic versions while Collegium continues branded sales.
• Gedeon RichtercoreOEM/ Whitelabel/ Licensing PartnerManufacturing partner for ENOBY and XTRENBO denosumab biosimilars. Richter manufactures under 2021 license agreement with Hikma holding exclusive US commercialization rights.
• Guardant HealthstrategicGTM or Marketing PartnerExclusive partnership agreement to bring Guardant360 Liquid CDx cancer diagnostic technology to the Middle East and North Africa region.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Teva Pharmaceutical Industries: Israel-based world's largest generic drug manufacturer with significant US and European generics, specialty, and biosimilars portfolios. Directly competes with Hikma across injectables, oral solids, and respiratory generics in North America and Europe.
• Sandoz: Novartis's former generics division and global leader in generic pharmaceuticals and biosimilars. Competes with Hikma in generic injectables, oral generics, and biosimilars across North America and Europe.
• Viatris: Major generics and specialty pharmaceutical company formed from Mylan/Upjohn combination, with broad US and international generics exposure. Overlaps with Hikma in oral generics, injectables, and specialty categories.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with significant US presence and operations in MENA markets. Directly comparable to Hikma as a multi-jurisdictional generics manufacturer with sterile injectable capabilities.
• Lupin Pharmaceuticals: Indian generic drug manufacturer with strong US oral solids, injectables, and specialty footprint. Competes head-to-head with Hikma in the US generics market, including respiratory and injectables categories.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with extensive US and European injectable and oral solid dose operations. Direct competitor in generic injectables and oral generics, with overlapping regulatory and manufacturing scale.
• Cipla: Indian-headquartered global pharmaceutical company with generics, specialty, and biosimilars businesses across emerging markets and developed economies. Comparable as a global generics player with multi-regional manufacturing.
• Endo International: US specialty and generic pharmaceutical company with significant sterile injectable and specialty generics portfolio. Competes with Hikma in US injectable generics and hospital-channel distribution.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based regional pharmaceutical manufacturer with branded generics focus across the MENA region. Direct MENA competitor to Hikma's Branded segment, particularly in Gulf Cooperation Council markets.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi Arabia-headquartered pharmaceutical manufacturer with branded generics across the MENA region. Competes directly with Hikma in Saudi Arabia and broader MENA markets, with overlapping manufacturing and product portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@HikmaPharma
• LinkedInlinkedin.com/company/hikma-pharmaceuticals
• Facebookfacebook.com/54603546979
• Instagraminstagram.com/hikma_pharma
• Xx.com/hikmapharma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A11 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hikma Pharmaceuticals